$345.63
1.25% day before yesterday
Nasdaq, Sep 06, 10:00 pm CET
ISIN
US91307C1027
Symbol
UTHR
Sector
Industry

United Therapeutics Corporation Stock price

$345.63
+23.67 7.35% 1M
+108.66 45.85% 6M
+125.74 57.18% YTD
+122.27 54.74% 1Y
+134.83 63.96% 3Y
+265.19 329.67% 5Y
+230.70 200.73% 10Y
Nasdaq, Closing price Fri, Sep 06 2024
-4.38 1.25%
ISIN
US91307C1027
Symbol
UTHR
Sector
Industry

Key metrics

Market capitalization $15.38b
Enterprise Value $12.91b
P/E (TTM) P/E ratio 15.88
EV/FCF (TTM) EV/FCF 14.66
EV/Sales (TTM) EV/Sales 4.93
P/S ratio (TTM) P/S ratio 5.88
P/B ratio (TTM) P/B ratio 2.69
Revenue growth (TTM) Revenue growth 23.96%
Revenue (TTM) Revenue $2.62b
EBIT (operating result TTM) EBIT $1.26b
Free Cash Flow (TTM) Free Cash Flow $880.60m
Cash position $2.97b
EPS (TTM) EPS $21.77
P/E forward 13.73
P/S forward 5.42
EV/Sales forward 4.55
Short interest 12.27%
Show more

Is United Therapeutics Corporation a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,914 stocks worldwide.

United Therapeutics Corporation Stock Analysis

Unlock Scores for Free

Analyst Opinions

16 Analysts have issued a United Therapeutics Corporation forecast:

8x Buy
50%
6x Hold
38%
2x Sell
13%

Analyst Opinions

16 Analysts have issued a United Therapeutics Corporation forecast:

Buy
50%
Hold
38%
Sell
13%

Financial data from United Therapeutics Corporation

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '24
+/-
%
2,617 2,617
24% 24%
100%
- Direct Costs 292 292
37% 37%
11%
2,325 2,325
22% 22%
89%
- Selling and Administrative Expenses 521 521
22% 22%
20%
- Research and Development Expense 480 480
45% 45%
18%
1,324 1,324
16% 16%
51%
- Depreciation and Amortization 61 61
16% 16%
2%
EBIT (Operating Income) EBIT 1,263 1,263
16% 16%
48%
Net Profit 1,069 1,069
23% 23%
41%

In millions USD.

Don't miss a Thing! We will send you all news about United Therapeutics Corporation directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

United Therapeutics Corporation Stock News

Positive
FXEmpire
8 days ago
Revenue growth and a recent regulatory win are driving shares of United Therapeutics Corporation (UTHR) upward.
Positive
Seeking Alpha
19 days ago
United Therapeutics Corporation remains a buy with strong growth potential and high returns on invested capital. Q2 FY'24 earnings show continued growth in sales and earnings, with upsides in its Tyvaso segment. The company has started share buybacks and is on track to reach a $3 billion revenue run rate by FY'25, supporting a valuation of $400/share.
Positive
Investors Business Daily
22 days ago
The top five biotech stocks today have several commonalities. Among them are strong ratings.
More United Therapeutics Corporation News

Company Profile

United Therapeutics Corp. operates as a biotechnology company, which engages in the development and commercialization of products for patients with chronic and life-threatening diseases. It markets and sells commercial therapies to treat pulmonary arterial hypertension and high-risk neuroblastoma. The firm also involves in the research and development of new indications and delivery devices for its product, and for the organ transplantation-related technologies. The company was founded by Martine A. Rothblatt on June 26, 1996 and is headquartered in Silver Spring, MD.

Head office United States
CEO Martine Rothblatt
Employees 1,168
Founded 1996
Website www.unither.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today